Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Cetuximab in Later-line Metastatic RAS Wild-type Colorectal Cancer
NCT07490119Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of becotatug vedotin in colorectal cancer (CRC), sponsored by Fudan University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07490119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490119.